Amarin Corp Plcuk (AMRN) Gross Margin (2013 - 2026)
Amarin Corp Plcuk (AMRN) reported Gross Margin of 39.37% for Q1 2026, down 2044.0% year-over-year from 2.03% in Q1 2025, and down 16.36% quarter-over-quarter from 47.07% in Q4 2025.
Amarin Corp Plcuk (AMRN) Gross Margin (2013 - 2026) Analysis & Trends
Amarin Corp Plcuk (AMRN) has 14 years of Gross Margin data on file, last reported at 39.37% in Q1 2026.
- Gross Margin for Q1 2026 came in at 39.37%, down 2044.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 52.37% (up 1752.0% YoY), and the FY2025 annual result was 56.57%, up 2098.0% from the prior year.
- Gross Margin eased to 39.37% in Q1 2026 per AMRN's latest filing, from 47.07% in the prior quarter.
- Over five years, Gross Margin peaked at 76.5% in Q1 2022 and troughed at 15.35% in Q4 2024.
- A 5-year average of 51.81% and a median of 55.75% in 2023 frame the typical range for Gross Margin.
- The sharpest annual moves came in 2024 and 2025: Gross Margin sank 7575 bps in 2024, then soared 6243 bps in 2025.
- A 5-year view of Gross Margin shows it stood at 70.48% in 2022, then slipped by 14 bps to 60.4% in 2023, then plunged by 125 bps to 15.35% in 2024, then jumped by 407 bps to 47.07% in 2025, then dropped by 16 bps to 39.37% in 2026.
- Business Quant data shows AMRN's Gross Margin at 39.37% in Q1 2026, 47.07% in Q4 2025, and 44.71% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | 75.42% |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 81.93% |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 66.31% |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 71.88% |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | 74.24% |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 68.16% |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 79.24% |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | -51.69% |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 70.22% |
| 10 | Amarin Corp Plcuk | 5.84 Bn | 5.66 Bn | 17.77 Mn | 39.37% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 39.37% |
| Dec 31, 2025 | 47.07% |
| Sep 30, 2025 | 44.71% |
| Jun 30, 2025 | 69.23% |
| Mar 31, 2025 | 59.81% |
| Dec 31, 2024 | -15.35% |
| Sep 30, 2024 | 38.48% |
| Jun 30, 2024 | 63.37% |
| Mar 31, 2024 | 56.45% |
| Dec 31, 2023 | 60.40% |
| Sep 30, 2023 | 45.15% |
| Jun 30, 2023 | 53.22% |
| Mar 31, 2023 | 55.75% |
| Dec 31, 2022 | 70.48% |
| Sep 30, 2022 | 69.94% |
| Jun 30, 2022 | 46.20% |
| Mar 31, 2022 | 76.50% |
| Dec 31, 2021 | 78.80% |
| Sep 30, 2021 | 78.73% |
| Jun 30, 2021 | 79.19% |